Yeon Sook KimShinichi OkaPloenchan ChetchotisakdAmanda ClarkeKhuanchai SupparatpinyoAnchalee AvihingsanonWinai RatanasuwanSasisopin KiertiburanakulKiat RuxrungthamSang Youn YangSusan GuoYa Pei LiuMoupali DasDo TranDamian McCollRoberto CoralesChris NguyenDavid PiontkowskyNational Center for Global Health and MedicineChungnam National UniversityKhon Kaen UniversityThe HIV Netherlands Australia Thailand Research CollaborationFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityFaculty of Medicine, Siriraj Hospital, Mahidol UniversityBrighton and Sussex University Hospitals NHS TrustGilead Sciences IncorporatedChiang Mai UniversityThai Red Cross AIDS Research Centre2020-01-272020-01-272019-05-04HIV Research and Clinical Practice. Vol.20, No.3 (2019), 73-8125787470257874892-s2.0-85076381646https://repository.li.mahidol.ac.th/handle/20.500.14594/51650© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian participants infected with human immunodeficiency virus (HIV)-1 through 96 or 144 weeks. Objective: In Asian population requiring treatment, it is imperative to have data specific to this group, particularly as there is a general concern that Asians with lower body weight have increased risk of tenofovir disoproxil fumarate (TDF)-related renal dysfunction. Methods: Studies -104 and 111 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-naive participants, comparing E/C/F/TAF versus E/C/F/TDF. Study 109 was a randomized, open-label, 96-week study conducted in virologically suppressed, ART-experienced participants, who switched to E/C/F/TAF from ritonavir/cobicistat-boosted atazanavir ATV+(RTV or COBI) + F/TDF regimens, from non-nucleoside reverse transcriptase inhibitors (NNRTI) + F/TDF regimens, or from E/C/F/TDF. Study 112 was a single arm, open-label, 144-week study conducted in HIV suppressed, ART-experienced participants with mild-moderate renal impairment, who switched to E/C/F/TAF. Results: Asian participants in these studies had sustained efficacy safety and tolerability. In Study 104/111, Asian participants achieved 93% virologic suppression on TAF vs 88% on TDF at week 144. At baseline, there were numerically more Asians with median CD4 counts < 200 cells/uL and VL > 100,000 c/mL. In Study 109, 95% of Asians on TAF vs 86% on TDF maintained virologic suppression at week 96. Lastly, in Study 112, 91% maintained virologic suppression at week 144. There were no discontinuations due to renal AE, no cases of PRT or Fanconi syndrome in any of the studies.Mahidol UniversityMedicineArticleSCOPUS10.1080/15284336.2019.1589232